The results suggested that both CD36 and EMAP II were upregulated on peripheral blood cells in NHL patients and that more than 90% of EMAP II+ peripheral lymphocytes were CD36+, while there was no expression compared to peripheral lymphocytes from healthy controls. Here, CD36 is linked to non-Hodgkin lymphoma.